CytoMed Therapeutics (GDTC) Current Leases (2021 - 2025)

CytoMed Therapeutics (GDTC) has disclosed Current Leases for 5 consecutive years, with $15121.4 as the latest value for Q4 2025.

  • Quarterly Current Leases rose 143.45% to $15121.4 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15121.4 through Dec 2025, up 143.45% year-over-year, with the annual reading at $15241.0 for FY2025, 152.04% up from the prior year.
  • Current Leases hit $15121.4 in Q4 2025 for CytoMed Therapeutics, up from $6211.2 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $15121.4 in Q4 2025 to a low of $4684.1 in Q4 2023.
  • Historically, Current Leases has averaged $7465.9 across 5 years, with a median of $5757.3 in 2021.
  • Biggest five-year swings in Current Leases: fell 15.69% in 2023 and later skyrocketed 143.45% in 2025.
  • Year by year, Current Leases stood at $5757.3 in 2021, then dropped by 3.5% to $5555.5 in 2022, then dropped by 15.69% to $4684.1 in 2023, then soared by 32.6% to $6211.2 in 2024, then surged by 143.45% to $15121.4 in 2025.
  • Business Quant data shows Current Leases for GDTC at $15121.4 in Q4 2025, $6211.2 in Q4 2024, and $4684.1 in Q4 2023.